Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Original title: “Notice of Interest Rate on Overdue Debts”
FDA inspectors found that Medline, which raised billions of dollars last year, failed to prevent repeat bacterial contamination of finished drug products.
Original title: “FDA hits Medline with warning letter over long-running contamination problem”
For Further Action See H.R.5538.
Original title: “HR 3850: Children's Preventive Health Act of 1983”
Referred to Subcommittee on Health.
Original title: “HR 3603: A bill to amend title XVIII of the Social Security Act to permit physicians serving without compensation on the governing or advisory boards of home health agencies to make patient certifications for home health services furnished by such agencies.”
See H.R.4170.
Original title: “HR 3590: Medicare Pacemaker Payment Reform and Patient Protection Act”
For Further Action See H.R.3851.
Original title: “HR 1554: A bill to amend the Federal Food, Drug, and Cosmetic Act to remove the prohibition against the labeling and advertising of a drug concerning its approval under that Act.”
Subcommittee Hearings Held.
Original title: “HR 3261: Health Care Cost Control Act of 1983”
Referred to Subcommittee on Health and the Environment.
Original title: “HR 3633: A bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen the authority of the Food and Drug Administration to control the use of drugs which present risks to the public and to secure data on adverse reactions to drugs, and for other purposes.”
Referred to Subcommittee on Health and the Environment.
Original title: “HR 3276: Comprehensive Health Care Improvement Act of 1983”
House Incorporated this Measure (Amended) in S.1538 as an Amendment.
Original title: “HR 3605: Drug Price Competition and Patent Term Restoration Act of 1984”
Subcommittee Hearings Held.
Original title: “HR 3272: Comprehensive Drug Penalty Act of 1983”
Referred to Subcommittee on Health and the Environment.
Original title: “HR 3616: A bill to amend title XVIII of the Social Security Act with respect to provision of home health services.”
For Further Action See H.R.5538.
Original title: “HR 3637: A bill to authorize the appropriation of funds for preventive health service programs for tuberculosis.”
Referred to Subcommittee on Health and the Environment.
Original title: “HR 3310: A bill to amend the Federal Food, Drug, and Cosmetic Act relating to the use of alcohol in confectionery.”
Clean Bill H.R.4901 Forwarded by Subcommittee to Full Committee in Lieu.
Original title: “HR 3299: Comprehensive Drug Penalty Act of 1983”
Referred to Subcommittee on Military Personnel and Compensation.
Original title: “HR 3884: Health Service Act”
Subcommittee Hearings Held.
Original title: “HR 3199: Drug and Biological Products Reform Act of 1996”
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
Original title: “House bill aims to crack down on China biotech deals”
Developers can then apply to begin ... larger trials aimed at proving the treatment is effective. Only after all that clinical testing is complete can developers apply to make a therapy available commercially. ... June 2, 2026 by Richard E. Poulin III · However, for rare diseases like AADC ... Developers can then apply to begin human testing, which usually begins with small-scale tests in a limited number of volunteers to assess the experimental treatment’s safety and pharmacological profile, followed by larger trials aimed at proving the treatment is effective. Only after all that clinical testing is complete can developers apply to make a therapy available commercially. ... June 2, 2026 by Richard E. Poulin III · However, for rare diseases like AADC deficiency, this setup is often impractical or even impossible. The U.K.'s MHRA is seeking feedback on a proposal to revamp how treatments for rare diseases are developed. The Medicines and Healthcare products Regulatory Agency (MHRA) is seeking public feedback on a proposal to revamp how rare disease treatments are developed in the U.K. The regulatory body wants input on a new plan that would streamline the clinical testing and approval processes to help get therapies to patients much faster. But even when there’s real promise in the science, treatments can take far too long to reach them because the regulatory pathways were not designed with rare diseases in mind,” added Sam Barrell, CEO of the life science medical research charity Lifearc. “This consultation is a chance to design a better way forward: one that enables therapies to reach patients faster without compromising safety. We’d encourage companies, researchers, clinicians and patient groups to get involved so the final framework reflects their expertise and experience.”
Original title: “New proposal seeks to fast-track rare disease treatments in UK”